Nexalin Technology (NXL) Current Deferred Revenue (2021)
Nexalin Technology (NXL) posted Current Deferred Revenue of $130000.0 for Q4 2021.
Powered by 
Analysis
Nexalin Technology (NXL) Current Deferred Revenue (2021) Analysis & Trends
Nexalin Technology has reported Current Deferred Revenue for 1 years, with the latest figure at $130000.0 in Q4 2021.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $130000.0 in Q4 2021; TTM through Dec 2021 was $130000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $130000.0, changed N/A from the prior year.
- Current Deferred Revenue was $130000.0 for Q4 2021 at Nexalin Technology.
- The five-year high for Current Deferred Revenue was $130000.0 in Q4 2021, with the low at $130000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 |